This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Sep;6(9):500-1.

doi: 10.1038/nrrheum.2010.134.

Psoriasis: Is ustekinumab superior to etanercept for psoriasis?

Annegret Kuhn¹, Thomas A Luger

Affiliations

PMID: 20808304
DOI: 10.1038/nrrheum.2010.134

Psoriasis: Is ustekinumab superior to etanercept for psoriasis?

Annegret Kuhn et al. Nat Rev Rheumatol. 2010 Sep.

. 2010 Sep;6(9):500-1.

doi: 10.1038/nrrheum.2010.134.

Authors

Annegret Kuhn¹, Thomas A Luger

Affiliation

¹ Department of Dermatology, University of Muenster, Von-Esmarch-Strasse 58, D-48149 Muenster, Germany. kuhnan@uni-muenster.de

PMID: 20808304
DOI: 10.1038/nrrheum.2010.134

No abstract available

PubMed Disclaimer

Similar articles

Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials.
Farhi D. Farhi D. Drugs Today (Barc). 2010 Apr;46(4):259-64. doi: 10.1358/dot.2010.46.4.1464839. Drugs Today (Barc). 2010. PMID: 20502723
Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.
Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM. Wan J, et al. Arch Dermatol. 2012 Apr;148(4):539-41. doi: 10.1001/archdermatol.2011.1399. Arch Dermatol. 2012. PMID: 22508884 Free PMC article. No abstract available.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group. Griffiths CE, et al. N Engl J Med. 2010 Jan 14;362(2):118-28. doi: 10.1056/NEJMoa0810652. N Engl J Med. 2010. PMID: 20071701 Clinical Trial.
Ustekinumab for the treatment of psoriasis.
Laws PM, Warren RB. Laws PM, et al. Expert Rev Clin Immunol. 2011 Mar;7(2):155-64. doi: 10.1586/eci.11.4. Expert Rev Clin Immunol. 2011. PMID: 21426253 Review.
[Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
Ortonne JP. Ortonne JP. Ann Dermatol Venereol. 2005 Aug-Sep;132(8-9 Pt 2):4S6-4S9. Ann Dermatol Venereol. 2005. PMID: 16335346 Review. French. No abstract available.

See all similar articles

Cited by

Toll-Like Receptors as a Therapeutic Target in the Era of Immunotherapies.
Farooq M, Batool M, Kim MS, Choi S. Farooq M, et al. Front Cell Dev Biol. 2021 Oct 4;9:756315. doi: 10.3389/fcell.2021.756315. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34671606 Free PMC article. Review.
Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
Lai CY, Su YW, Lin KI, Hsu LC, Chuang TH. Lai CY, et al. J Immunol Res. 2017;2017:7807313. doi: 10.1155/2017/7807313. Epub 2017 Aug 13. J Immunol Res. 2017. PMID: 28894754 Free PMC article. Review.

References

1. Lancet. 2009 Feb 21;373(9664):633-40 - PubMed
1. J Immunol. 2005 Aug 15;175(4):2721-9 - PubMed
1. Trends Immunol. 2006 Jan;27(1):17-23 - PubMed
1. N Engl J Med. 2010 Jan 14;362(2):118-28 - PubMed
1. Lancet. 2008 May 17;371(9625):1675-84 - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information